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Abstract
Crohn’s disease (CD) and celiac disease (CelD) are chronic intestinal inflammatory diseases, involving genetic and
environmental factors in their pathogenesis. The two diseases can co-occur within families, and studies suggest that CelD
patients have a higher risk to develop CD than the general population. These observations suggest that CD and CelD may
share common genetic risk loci. Two such shared loci, IL18RAP and PTPN2, have already been identified independently in
these two diseases. The aim of our study was to explicitly identify shared risk loci for these diseases by combining results
from genome-wide association study (GWAS) datasets of CD and CelD. Specifically, GWAS results from CelD (768 cases,
1,422 controls) and CD (3,230 cases, 4,829 controls) were combined in a meta-analysis. Nine independent regions had
nominal association p-value ,1.061025 in this meta-analysis and showed evidence of association to the individual diseases
in the original scans (p-value,161022 in CelD and,161023 in CD). These include the two previously reported shared loci,
IL18RAP and PTPN2, with p-values of 3.3761028 and 6.3961029, respectively, in the meta-analysis. The other seven had not
been reported as shared loci and thus were tested in additional CelD (3,149 cases and 4,714 controls) and CD (1,835 cases
and 1,669 controls) cohorts. Two of these loci, TAGAP and PUS10, showed significant evidence of replication (Bonferroni
corrected p-values,0.0071) in the combined CelD and CD replication cohorts and were firmly established as shared risk loci
of genome-wide significance, with overall combined p-values of 1.55610210 and 1.38610211 respectively. Through a meta-
analysis of GWAS data from CD and CelD, we have identified four shared risk loci: PTPN2, IL18RAP, TAGAP, and PUS10. The
combined analysis of the two datasets provided the power, lacking in the individual GWAS for single diseases, to detect
shared loci with a relatively small effect.
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Introduction
Crohn’s disease (CD) and celiac disease (CelD) are both chronic
intestinal inflammatory diseases. In CD inflammation can occur
throughout the gastrointestinal tract but most commonly affects
the ileal part of the small intestine. While the causative antigen(s)
for this inflammation is unknown, it is thought that the disease
arises as a reaction to the normal commensal flora of the bowel in
a genetically susceptible individual [1,2]. In CelD inflammation is
limited to the small intestine. CelD is caused by a reaction to
gluten, a dietary peptide present in wheat, barley and rye [3,4]. In
both CelD and CD contact between antigens and antigen-
presenting cells (APCs) seems to be facilitated by an initial increase
in intestinal permeability [5]. In both diseases the subsequent
inflammatory response follows a T helper 1 pattern characterized
by tumor necrosis factor beta (TNF-b) and interferon gamma
(IFN-c) production and a T helper 17 response marked by the
production of interleukin 17 [5].
Although uncommon, it has been observed that CelD and CD
can co-occur within families or even within individual patients;
there appears to be a greater prevalence of CD among CelD
patients than in the general population, although the relatively low
prevalence of CD makes it difficult to establish this effect [6]. It is
now well accepted that the risk for CD and CelD is partly
determined by genetic factors, and recently many genetic risk
factors for CelD and CD have been identified. Two genetic risk
loci were previously shown to be shared between CelD and CD: a
locus on 18p11 containing the PTPN2 (protein tyrosine phospha-
tase, non-receptor type 2) gene and a locus on 2q12 containing the
IL18RAP (interleukin 18 receptor accessory protein) gene [7–13].
While these observations confirm the existence of shared risk loci
for CD and CelD, additional such shared risk loci are likely to
exist.
There are two possible approaches for identifying shared risk
loci. One approach is to test known risk loci from one disease in
patient-control cohorts from the other disease. This approach has
already been successfully applied in a cross study between CelD
and type 1 diabetes (T1D), where four shared risk loci were
identified some of which were previously unknown to be associated
to CelD [11]. However, this approach relies on previously
identified risk alleles, indicating that there probably are many
more unknown common risk loci for T1D and CelD. In addition,
some of the shared loci will not have a large enough effect in the
individual diseases to have been identified by previous genetic
studies. A second approach that tackles this problem is to analyze
genetic data from two similar diseases as a single unified disease
phenotype against healthy controls. Such an analysis would be
expected to dilute disease-specific genetic associations, but increase
the power for finding shared genetic risk loci of small effect in the
individual diseases. The availability of genome-wide association
studies (GWAS) performed in both CelD and CD provides large
case-control genotyping datasets that enabled us to perform a
cross-disease genome-wide meta-analysis in the aim of identifying
novel shared risk loci.
To identify novel shared risk loci between CelD and CD, we
performed a meta-analysis of two recently published GWAS: a
large meta-analysis of three CD GWAS by the International IBD
Genetics Consortium and a CelD GWAS in a British population.
To confirm identified risk loci, we used a combination of Italian
and Dutch CD cohorts and of British, Italian and Dutch CelD
cohorts.
Results
Meta-analysis
We have performed a meta-analysis of 471,504 SNPs from
genome-wide datasets of CD (3230 cases, 4829 controls) and CelD
(768 cases, 1422 controls) in order to identify shared risk loci
between these 2 diseases.
A quantile-quantile (Q-Q) plot of the association p-values for
single-SNP Z scores from the meta-analysis was performed (Figure
S1) and shows an excess of significant associations above what
would be expected by chance. We observe a low inflation factor of
1.08, which is expected given the inflation observed in each of the
original studies: 1.05 for CelD and 1.16 for CD. A Manhattan plot
of the current study (Figure S2) highlights many strong association
signals, several of which corresponding to previously reported CD
and CelD loci; however, most of these show strong association in
only one of the 2 diseases and have thus not been followed up due
to the design of the current study. In addition, given the design of
the original CelD GWAS, which included only individuals that
were positive for the risk-associated allele HLA-DQ2, association to
the major histocompatibility complex (MHC) region in CelD was
of no relevance since it was artificially inflated. Therefore the
MHC region (Chr6:22700000..35000000 from the NCBI B36
genome build) was removed from our analysis.
The meta-analysis of the CD and CelD datasets identified 25
SNPs, from 10 independent regions, that met our criteria for
association (association with CelD at p-value ,161022 and with
CD at p-value,161023 in the original scans, as well as a nominal
association p-value more significant than 1.061025 in the meta-
analysis) (Table 1 and Table S2). This is more than expected by
chance, as we would expect no more than 3 independent regions
to meet our criteria, which encouraged us to explore these specific
loci further.
The strongest association signal identified in our scan was to the
well accepted CD associated risk locus CARD15 (p-values of
3.42610232, 3.7761023 and 1.30610221 in the CD, CelD and
scan datasets respectively). Given the strength and the width of the
association signal peak at this locus in the CD dataset, our chances
of detecting a false positive shared signal at this locus in the scan
were artificially increased. Because of this, the CARD15 locus was
Author Summary
Celiac disease and Crohn’s disease are both chronic
inflammatory diseases of the digestive tract. Both of these
diseases are complex genetic traits with multiple genetic
and non-genetic risk factors. Recent genome-wide associ-
ation (GWA) studies have identified some of the genetic
risk factors for these diseases. Interestingly, in addition to
some similarities in phenotype, these studies have shown
that CelD and CD share some genetic risk factors.
Specifically, by comparing the results of independent
GWA studies of CD and CelD, two genetic risk loci were
found in common: the PTPN2 locus and the IL18RAP locus.
Therefore, in order to directly test for additional shared
genetic risk factors, we combined the GWA results from
two large studies of CelD and CD, essentially creating a
combined phenotype with anyone with CD or CelD being
coded as affected. Association results were then replicated
in additional cohorts of CelD and CD. It is expected that
shared risk loci should show association in this analysis,
whereas the signal of risk loci specific to either of the two
diseases should be diluted. With this method of meta-
analysis, we identified next to PTPN2 and IL18 RAP two loci
harbouring TAGAP and PUS10 as shared risk loci for Crohn’s
disease and celiac disease at genome-wide significance.
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not moved forward to replication. An evaluation of the association
signal in the in silico CelD GWAS replication datasets confirmed
that this locus did not show replication in CelD. Several of the
SNPs meeting our criteria for association mapped to the known
shared risk loci IL18RAP and PTPN2. Identifying these shared risk
loci in the initial phase of our analysis provides proof of the
effectiveness of our method. Interestingly, these two loci either
reach or are very near genome-wide significance in the current
meta-analysis (p-value of 8.3761028 for IL18RAP and of
6.3961029 for PTPN2), validating their previously identified role
in both CD and CelD. The remaining 12 SNPs were located in
seven independent regions and for each of these loci we selected
the most associated SNP for testing for evidence of replication.
Replication phase
All SNPs selected for follow-up were genotyped in additional
replication cohorts of CelD patients (n = 3149) and healthy
controls (n = 4714) and of CD patients (n = 1941) and healthy
controls (n = 1669). Given that these putative shared risk loci were
selected through the combined analysis of our CD and CelD scan
cohorts, a positive threshold for replication was therefore set at a
corrected p-value of 0.0071 (Bonferroni corrected p-value of 0.05
for 7 independent tests) in the combined analysis of CD and CelD
replication cohorts.
Only two of the 7 loci tested, PUS10 (pseudouridylate synthase
10; RefSeq NM_144709.2) and TAGAP (T-cell activation GTPase
activating protein; RefSeq NM_054114), showed significant
replication (p-values of 6.0361027 and 3.0361026 respectively)
with matching direction of association between the scan and
replication datasets, as well as replication p-values more significant
than 0.05 in both CD and CelD replication cohorts independently
(Table 1). While neither PUS10 nor TAGAP were identified as loci
of genome-wide significance in the combined dataset from each
disease (p-values = 1.3461026 and 7.0061027 in CelD and p-
values = 6.1661028 and 2.1361026 in CD respectively), both
reach genome-wide significance in a combined analysis of CD and
CelD cohorts (p-values of 1.38610211 and 1.55610210 respec-
tively). Based on the results calculated from the replication
datasets, we also observe that the effects at these 2 loci are similar
in size and direction for both CD and CelD (Table 1).
Discussion
By performing a meta-analysis of GWAS data from CD and
CelD as a single disease phenotype, we have identified four risk
loci shared by these 2 diseases: PTPN2, IL18RAP, TAGAP and
PUS10. This meta-analysis approach provided the power, lacking
in individual disease-specific GWAS datasets, to identify shared
risk loci with small effects in each single disease. This approach is a
powerful and versatile way of identifying shared risk loci. In fact,
two of the shared loci described here, TAGAP and PUS10, would
not have reached genome-wide significance without the power
gained from the combined samples (scan and replication) of these
2 diseases. As the GWAS for the individual diseases increase in
power, we can expect the power of the current approach to also
increase enabling us to identify further shared loci.
The TAGAP locus identified in the current study as a shared risk
factor for CD and CelD is located on chromosome 6q25.3, within
a 200-kb block of linkage disequilibrium (LD). This TAGAP locus
was previously identified as a CelD risk locus [9] but not found
in previous studies of CD. TAGAP is the best candidate of four
genes in this region of strong LD [9]. TAGAP is a member of
the Rho-GTPase protein family, which release GTP from GTP-
bound Rho, thereby acting as a molecular switch. The gene is
expressed in activated T cells and appears to be important for
modulating cytoskeletal changes [14]. Little is known about the
Table 1. Results from the meta-analysis, replication, and combined analysis.
Initial Analysis Replication Combined Analysis
Locus SNP
Risk
Allele CelD CD
meta-
analysis CelD CelD CD CD
meta-
analysis CelD CD
meta-
analysis
p-value p-value p-value OR** p-value OR** p-value p-value p-value p-value p-value
IL18RAP* rs6708413 G 6.5061025 2.0561025 8.3761028 N.T. N.T. N.T. N.T. N.T.
PTPN2* rs16939895 C 2.0661023 4.6261029 6.3961029 N.T. N.T. N.T. N.T. N.T.
PUS10 rs10188217 C 8.3061023 6.1461026 3.3361026 1.14 4.5261025 1.16 2.9061023 6.0361027 1.3461026 6.1661028 1.38610211
CCDC91 rs10771427 G 2.0961023 5.7261025 4.0061026 1.00 0.94 1.02 0.79 0.80
3q13 rs1517605 T 5.6061024 1.9861024 3.2261026 1.02 0.67 0.98 0.73 0.95
TAGAP rs212388 C 1.2261024 1.2361025 7.8661027 1.14 8.8861025 1.10 0.048 3.0361025 7.0061027 2.1361026 1.55610210
KCNG4 rs40254 A 5.6961023 2.9761025 6.5861026 0.96 0.19 1.00 0.98 0.34
C10orf72 rs4317904# A 2.0961024 2.8061024 1.8761026 1.04 0.26 1.06 0.24 0.10
FERMT1 rs6516104# T 5.8761025 6.1961024 1.3661026 1.04 0.47 0.97 0.73 0.76
The meta-analysis was performed using a directional non-weighed Z-score method as explained in the methods section. Combined analyses were performed using a
directional weighed Z-score method within diseases and a directional non-weighed Z-score method between diseases. Results for the combined analysis are given only
for the SNPs that pass the replication thresholds (directionality in each disease and p-value ,0.0071 for the combined replication data).
*, IL18RAP and PTPN2 were not followed up because they are known shared risk loci for CD and CelD;
**, OR for the replication is reported for the allele identified as the risk allele in the initial scan;
#, SNPs that were imputed in the CelD replication datasets.
N.T., not tested. CelD = Celiac disease, CD = Crohn’s disease, SNP = single nucleotide polymorphism, IL18RAP = interleukin 18 receptor accessory protein, PTPN2 =
protein tyrosine phosphatase, PUS10 = pseudouridylate synthase 10, CCDC91 = coiled-coil domain containing 91, TAGAP = T-cell activation RhoGTPase activating
protein, KCNG4 = potassium voltage-gated channel, subfamily G, member 4, non-receptor type 2, C10orf72 = Chromosome 10 open reading frame 72, FERMT1 = -
fermitin family homolog 1, 3q13, 9q13, 17p13 = intergenic regions.
doi:10.1371/journal.pgen.1001283.t001
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exact role of TAGAP in immune function, but it has been found to
be co-regulated with IL2 and is expected to play a role in T-cell
activation [14].
The current study also identifies a shared risk locus between CD
and CelD in the PUS10 gene region, a locus previously described
as a risk locus for CD [15]. This locus was recently identified as a
risk locus in both ulcerative colitis (UC) and CelD, indicating that
this locus may be a shared risk locus for these three diseases [7,16].
This latter finding further validates the approach use in this study
to identify risk factors that are shared across diseases. Interestingly,
the UC study identified three independent signals in this region
which seem to be shared differently across these three diseases: one
signal seems to be shared only between CD and UC, a second only
between CelD and UC, while the third, identified in the current
study, seems shared between all three diseases. Further analysis of
this locus will be necessary in order to clarify the role of these
different alleles in disease risk.
In this study we aimed to find shared genetic risk factors for
CelD and CD by meta-analysis of GWAS data of both diseases,
defining a single phenotype for these analyses. Using readily
available data, we were able to reliably establish four shared loci:
PTPN2, IL18RAP, TAGAP and PUS10. For many diseases with
overlapping phenotypic characteristics, GWAS data is available
and joint analysis of GWAS datasets of these related diseases could
lead to the identification of many new shared susceptibility loci.
Materials and Methods
Subjects
For the CD aspect of the meta-analysis, we used the pre-
viously published data (available at http://www.broadinstitute.org/
,jcbarret/ibd-meta/) from the International Inflammatory Bowel
Disease Genetics Consortium (IIBDGC) meta-analysis of 3230 CD
cases and 4829 healthy controls taken from three independent CD
GWAS (Table S1) [15]. A more in depth description of these cohorts
and their origin can be obtained from the original publication of this
meta-analysis.
Two independent cohorts were used for the CD replication
phase (Table S1). The first consisted of 1217 Dutch CD cases from
three Dutch university medical centers: the Academic Medical
Centre Amsterdam (n= 661), the University Medical Centre
Groningen (n= 322) and the University Medical Centre Leiden
(n = 234); the 804 Dutch controls used for this replication cohort
were obtained from cohorts of healthy partners of IBD patients
from the UMC Leiden (n= 151) and the UMC Groningen
(n = 120) and from healthy blood donors recruited through the
Sanquin Blood bank by the UMC Utrecht and the VUMC
Amsterdam (n= 533) [17,18]. The second replication cohort
consisted of an Italian IBD case – control cohort (724 CD patients
and 892 controls) collected at the S. Giovanni Rotondo ‘‘CSS’’
(SGRC) Hospital in Italy. This cohort has previously been used
and characterized in several association reports [19,20].
All patients and controls were of European Caucasian descent.
The diagnosis of CD required objective evidence of inflammation
from radiologic, endoscopic, and/or histopathologic evaluation.
All affected subjects fulfilled clinical criteria for CD. Recruitment
of study subjects was approved by local and national institutional
review boards, and informed consent was obtained from all
participants.
For the celiac disease aspect of this meta-analysis, data from a
previously published genome-wide scan (768 British cases, 1422
British controls) for CelD was used (Table S1). A more in depth
description of this cohorts and its origin can be obtained from the
original publications [9,12].
For the replication phase in CelD we used the genotyping
results from a second celiac GWAS in three independent CelD
cohorts (Table S1). From this study we received data from 3149
cases and 4714 controls from three European populations (UK,
the Netherlands and Italy) genotyped on Custom Illumina Human
670-Quad, Hap550 and 1.2 M slides [13]. UK CelD cases were
recruited from hospital outpatient clinics (n = 434) and directly
through Coeliac UK advertisement (n = 1415) [9]; UK controls
were recruited from the 1958 birth cohort and UK National Blood
Service for the Welcome Trust Case Control Consortium
(WTCCC) (n= 3786). Dutch CelD cases were collected by the
UMC Utrecht, Leiden UMC and VUMC Amsterdam from
outpatient clinics (n = 803); Dutch controls were recruited through
the Sanquin Blood bank by the UMC Utrecht and the VUMC
Amsterdam (n= 385). Italian CelD cases (n = 497) and controls
(n = 543) were collected by a CelD referral centre (Centro per la
prevenzione e diagnosi della malattia celiaca, Fondazione IRCCS
Ospedale Maggiore Policlinico) in northern Italy.
All affected individuals were unrelated and were diagnosed
according to the revised ESPGAN criteria (1990). The cohorts
encompassed individuals that showed a Marsh II or Marsh III
lesion in the initial diagnostic small-bowel biopsy specimens, or
presented with dermatitis herpetiformis and were HLA-DQ2
positive. Recruitment of study subjects was approved by local
and national institutional review boards, and informed consent
was obtained from all participants. Some controls were shared
between the WTCCC component of the CD meta-analysis and
the two UK CelD cohorts (one used in the original scan and one
used as replication). This was taken into account as explained in
the meta-analysis description.
Imputation of GWAS data
Imputation of the CelD datasets used in the initial and the
replication phases of this study were performed with BEAGLE
using HapMap phase II and HapMap phase III as reference
datasets [21]. A minimum quality score for statistical certainty of
the imputation of 0.98 was adhered to.
Imputation of the CD dataset for the initial CD-CelD meta-
analysis was performed with the programs MACH and IMPUTE,
using HapMap phase II as a reference dataset, as previously
described [15,22,23].
Meta-analysis
For the original CD dataset, association tests were described
previously [15]. Briefly, results for each SNP from three
independent GWAS were summarized as Z-scores and combined
in a weighted fashion into a single test statistic; imputation
uncertainty was taken into account into Z-score and weight
calculation using empirical variance calculated from allele dosage.
For the original CelD GWAS scan, best guess imputed genotype
frequency data was obtained, and association P-values were
calculated using chi-square tests (1 df) of SNP allele counts.
The initial meta-analysis was performed using the statistical
program R (http://www.r-project.org/). For both the CD and the
CelD dataset the p-values signifying the evidence for association
were converted to directional Z-scores, and an overall Z-score and
two-tailed p-value for the average of the individuals was
subsequently calculated. Given the fact that some controls were
shared between one component of the CD meta-analysis and the
CelD scan, we expect a correlation of 0.187 between CD and
CelD Z-scores. We took this correlation into account in the
variance term of the overall Z-score [24].
Unweighed Z-scores were used when combining the data from
CD and CelD in the initial meta-analysis, since the CD cohort was
Shared Risk Loci for Celiac and Crohn’s Disease
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substantially larger than the CelD cohort and weighing would lead
to an overrepresentation of the CD signal in the meta-analysis.
A locus was selected for replication when SNPs met the
following criteria: a p-value for the locus of ,161025 in the meta-
analysis, in combination with a p-value of ,161022 in the CelD
dataset and a p-value of ,161023 in the CD dataset. Different
thresholds for CD and CelD for inclusion in the replication phase
were used in order to reflect the difference in power between the
scans for the two phenotypes. For each of the loci that met these
criteria, the most strongly associated SNP was analyzed in the CD
and CelD replication cohorts.
In order to evaluate the expected number of SNPs that would
pass our thresholds (p-value ,161022, ,161023 and ,161025
for CelD, CD and meta-analysis, respectively) by chance, we first
evaluated the probability for a particular SNP to reach those
thresholds under the null hypothesis of no association and the
expected correlation between the two datasets. This probability can
be evaluated from the distribution of two correlated normal
variables (correlation of 0.186), combined as described for the
meta-analysis. We evaluated this probability to be approximately
6.061026. If the 468,378 SNPs tested in the scan were independent,
we would then expect less than 3 (468,378*6.061026) independent
SNPs to be selected by chance. Under a binomial model, we
evaluated the probability that 9 or more independent SNPs passes
our thresholds to be lower than 0.0025. Those are obviously upper
bounds, as we know correlation exists among the SNPs tested.
Replication phase
For replication in CD, SNPs selected for testing were designed
into multiplex assays, and genotyped using primer extension
chemistry and mass spectrometric analysis (iPlex assay, Sequenom,
San Diego, California, USA) on the SequenomMassArray. This was
performed at the Laboratory for Genetics and GenomicMedicine of
Inflammation (www.inflammgen.org) of the Universite´ de Montreal.
Quality control was performed, excluding samples showing .10%
missing data, as well as SNPs with .10% missing data or
significantly out of Hardy-Weinberg equilibrium (p-value ,0.001).
The overall genotyping call rate in the CD replication dataset
following quality control analyses was .99%. The CD replication
datasets from the two groups (Dutch and Italian) were combined and
analyzed using a weighted and directional Z-score approach.
For replication in CelD, genotype frequencies and association
data for five replication SNPs were obtained from genome-wide
genotyping datasets on Illumina Human 670Quad or 610Quad
Genotyping BeadChips (Illumina, Inc., San Diego, CA,). Each
GWAS dataset was analyzed using PLINK 1.05 and association p-
values were calculated using chi-square tests (1 df) of SNP allele
counts [25]. Two of the replication SNPs were not included on the
Illumina Human 670Quad or 610Quad Genotyping BeadChips.
For these SNPs best guess genotype frequency data was obtained
by imputation as described above, and association p-values were
calculated using chi-square tests (1 df) of SNP allele counts The
CelD replication datasets from the three groups (UK, the
Netherlands and Italy) were combined and analyzed using a
weighted and directional Z-score approach.
Since selection of specific SNPs for replication was based on
their association p-values in the combined CD-CelD dataset, a
significant threshold for replication was set at a Bonferroni
corrected p-value of 0.05 for 7 independent tests (p-value more
significant than 0.0071) in the combined CD-CelD replication
dataset. As for the initial meta-analysis, the data from the
replication in the CD and CelD cohorts were combined through
an unweighed Z-score approach. In addition, for a SNP to be
replicated, both effect and direction of association trend needed to
match between scan and replication within each disease.
For each SNP showing positive replication, an overall disease-
specific association p-value, combining the scan and replication
data, was also calculated using a weighted meta-analysis approach.
Finally, an overall CD-Celiac meta-analysis of the scan and
replication phases of this study was obtained, by combining these
within-CD and within-Celiac datasets in an unweighed meta-
analysis. Given the fact that some controls were shared between
the within-CD and the within-CelD, we expect a correlation of
0.149 between CD and CelD Z-scores. As for the initial scan, we
took this correlation into account in the variance term of the
overall Z-score as per Lin and colleagues [24].
Supporting Information
Figure S1 Q-Q plot of meta-analysis scan. A meta-analysis scan of
471,504 SNPs from genomewide datasets of CD and CelD was
performed using a directional non-weighed Z-score method (as
explained in the methods section). TheQ-Q plot was generated from
the p-values for single-SNP Z scores. Given the strength of associ-
ation signal for the MHC region (chr6:22,700,000.35,000,000) in
CelD, this region overwhelmed the Q-Q plot and was therefore
removed from the dataset for purpose of clarity; removing the MHC
region had little impact on the observed inflation.
Found at: doi:10.1371/journal.pgen.1001283.s001 (0.06 MB
DOC)
Figure S2 Manhattan plot of meta-analysis scan. A meta-analysis
scan of 471,504 SNPs from genomewide datasets of CD and CelD
was performed using a directional non-weighed Z-score method (as
explained in the methods section). TheManhattan plot was generated
from the p-values for single-SNP Z scores. Given the strength of
association signal for the MHC region (chr6:22,700,000.35,000,000)
in CelD, this region overwhelmed the Manhattan plot and was
therefore removed from the dataset for purpose of clarity.
Found at: doi:10.1371/journal.pgen.1001283.s002 (0.10 MB
DOC)
Table S1 Subjects included in study.
Found at: doi:10.1371/journal.pgen.1001283.s003 (0.14 MB
DOC)
Table S2 Complete list of associated markers from meta-
analysis.
Found at: doi:10.1371/journal.pgen.1001283.s004 (0.01 MB
XLSX)
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